Polymeric treatment compositions

• US 10,201,562 B2
• Filed: 03/16/2018
• Issued: 02/12/2019
• Est. Priority Date: 06/14/2012
• Status: Active Grant

• Current Assignee: Microvention Incorporated (Terumo Corporation)
• Original Assignee: Microvention Incorporated (Terumo Corporation)
• Inventors: Cruise, Gregory M., Constant, Michael J., Garretson, Joshua
• Primary Examiner(s): Song, Jianfeng
• Application Number:
  US15/924,028
• Publication Number:
  US 20180200288A1
• Time in Patent Office: 333 Days
• CPC Class Codes: A61K 31/78 of acrylic acid or derivatives thereof
• CPC Class Codes: A61K 31/785 Polymers containing nitrogen
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 24/0089 containing inorganic fillers not covered by groups A61L24/0078 or A61L24/0084
• CPC Class Codes: A61L 24/046 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L24/043 takes precedence
• CPC Class Codes: A61L 2430/36 for embolization or occlusion, e.g. vaso-occlusive compositions or devices
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Compositions are described comprising a polymer; a non-physiological pH solution; and a visualization agent; wherein the polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

Claims

1. A composition comprising:

a biocompatible polymer comprising;

a first monomer selected from a group consisting of aminopropyl methacrylamide, aminoethyl methacrylamide, aminoethyl methacylate, aminopropyl methacylate, N-(3-methylphridine)acrylamide, N-(2-(4-aminophenyl)ethylacrylamide, N-(4-aminobenzyl)acrylamide, N-(2-4-imidazolyl)ethyl)acrylamide, and combinations thereof; and

a second monomer including an acrylate, acrylamide, a derivative thereof, or a combination thereof;

a solution with a non-physiological pH; and

a visualization agent;

wherein the biocompatible polymer is soluble in the solution and insoluble at a physiological pH at a treatment site;

wherein the visualization agent is an iodinated compound, barium sulfate, tantalum, superparamagnetic iron oxide, gadolinium molecules or a combination therefore.

2. The composition of claim 1, wherein the visualization agent is a particulate.

3. The composition of claim 1, wherein the visualization agent has a concentration of about 5% to about 65%.

4. The composition of claim 1, wherein the polymer is a reaction product of two different monomers.

5. The composition of claim 1, wherein the polymer is a reaction product of three different monomers.

6. The composition of claim 1, wherein the non-physiological pH solution is aqueous.

7. The composition of claim 1, wherein the non-physiological pH solution is water.

8. The composition of claim 1, wherein the non-physiological pH solution has a pH of less than about 6.

9. The composition of claim 1, wherein the non-physiological pH solution has a pH of greater than about 8.

10. The composition of claim 1, wherein the polymer has a concentration of about 1% w/w to about 35% w/w.

11. A composition comprising:

a first aqueous solution at non-physiological pH;

a biocompatible polymer comprising a first monomer selected from a group consisting of aminopropyl methacrylamide, aminoethyl methacrylamide, aminoethyl methacylate, aminopropyl methacylate, N-(3-methylphridine)acrylamide, N-(2-(4-aminophenyl)ethylacrylamide, N-(4-aminobenzyl)acrylamide, N-(2-4-imidazolyl)ethyl)acrylamide, and combinations thereof; and

a second monomer including an acrylate, acrylamide, a derivative thereof, or a combination thereof;

wherein the polymer has a concentration of from about 1% to 35% w/w, that is soluble in the first aqueous solution at non-physiological pH and insoluble in a second aqueous solution at physiological pH; and

a particulate visualization agent at a concentration of from about 5% w/w to about 65% w/w;

wherein the visualization agent is an iodinated compound, barium sulfate, tantalum, superparamagnetic iron oxide, gadolinium molecules or a combination therefore.

12. The composition of claim 11, wherein the visualization agent is a particulate.

13. The composition of claim 11, wherein the visualization agent has a concentration of about 20% to about 60%.

14. The composition of claim 11, wherein the polymer is a reaction product of two different monomers.

15. The composition of claim 11, wherein the polymer is a reaction product of three different monomers.

16. The composition of claim 11, wherein the non-physiological pH solution is water.

17. The composition of claim 11, wherein the non-physiological pH solution has a pH of less than about 6.

18. The composition of claim 11, wherein the non-physiological pH solution has a pH of greater than about 8.